Palbociclib in breast cancer neoadjuvant setting
Autops. Case Rep
; 11: e2021309, 2021. graf
Artigo
em Inglês
| LILACS
| ID: biblio-1285407
Biblioteca responsável:
BR26.7
ABSTRACT
Cyclin-dependent kinase 4/6 inhibitors represent a major advance in breast cancer treatment, emerging as the standard of care of the initial treatment of hormone receptor-positive and HER2-negative metastatic breast cancer. Their activity in this subset of patients leads to interest in their use in the adjuvant and neoadjuvant settings. This case report presents a real-life case of cyclin-dependent kinase 4/6 inhibitors use in a patient initially considered to have stage IV luminal HER2-negative breast cancer with liver metastasis. The discrepancy of treatment response between the breast tumor and liver node led to a repetition of the liver biopsy, which revealed metastasis of a neuroendocrine tumor of unknown primary. The breast tumor showed a partial response, and the initial therapeutic strategy was then redefined for curative intent. While cyclin-dependent kinase 4/6 inhibitors are not yet approved for clinical practice in the neo / adjuvant treatment of hormone receptor-positive breast cancer, this case report portrays a successful example of its application in a neoadjuvant setting.
Texto completo:
Disponível
Coleções:
Bases de dados internacionais
Base de dados:
LILACS
Assunto principal:
Neoplasias da Mama
/
Carcinoma
/
Quinase 4 Dependente de Ciclina
/
Quinase 6 Dependente de Ciclina
Limite:
Adulto
/
Feminino
/
Humanos
Idioma:
Inglês
Revista:
Autops. Case Rep
Assunto da revista:
Anatomia
/
Patologia Cl¡nica
/
Patologia Legal
Ano de publicação:
2021
Tipo de documento:
Artigo
País de afiliação:
Portugal
Instituição/País de afiliação:
Centro Hospitalar de Trás-os-Montes e Alto Douro EPE/PT